InMed Pharmaceuticals Inc. (NASDAQ:INM) Short Interest Up 1,125.9% in January

InMed Pharmaceuticals Inc. (NASDAQ:INM) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 33,100 shares, a growth of 1,125.9% from the January 15th total of 2,700 shares. Based on an average daily volume of 459,500 shares, the short-interest ratio is currently 0.1 days.

InMed Pharmaceuticals Trading Up 1.6 %

NASDAQ INM traded up $0.05 during trading hours on Friday, hitting $3.15. The company’s stock had a trading volume of 14,301 shares, compared to its average volume of 958,505. The company has a quick ratio of 4.22, a current ratio of 5.07 and a debt-to-equity ratio of 0.08. InMed Pharmaceuticals has a twelve month low of $2.41 and a twelve month high of $15.70. The stock has a fifty day moving average of $4.30 and a 200 day moving average of $4.71. The firm has a market capitalization of $2.27 million, a P/E ratio of -0.23 and a beta of 0.19.

InMed Pharmaceuticals (NASDAQ:INM) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($3.64) EPS for the quarter. InMed Pharmaceuticals had a negative return on equity of 65.74% and a negative net margin of 137.41%.

InMed Pharmaceuticals Company Profile

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.